Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 1,500 shares, a decline of 90.7% from the February 28th total of 16,100 shares. Based on an average daily volume of 45,700 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Cocrystal Pharma in a research report on Wednesday, January 22nd.

Cocrystal Pharma Trading Up 3.5 %

Shares of COCP traded up $0.05 during midday trading on Friday, hitting $1.48. 2,812 shares of the company’s stock traded hands, compared to its average volume of 29,294. The firm’s fifty day moving average is $1.82 and its 200-day moving average is $1.93. Cocrystal Pharma has a 1 year low of $1.35 and a 1 year high of $3.26. The stock has a market capitalization of $15.06 million, a price-to-earnings ratio of -0.80 and a beta of 2.35.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.